Epidural opioid analgesia is commonly employed as a therapeutic modality in the management of pain during labor. The general perception among health-care providers is that administered drugs remain in the maternal epidural space and do not compromise the respiratory status of newborns. We describe the clinical course of two newborns who developed respiratory depression following epidural fentanyl analgesia requiring administration of naloxone. The article further reviews the maternal-fetal-placental pharmacokinetics of epidural fentanyl and the possible mechanisms for the causation of neonatal respiratory depression.
INTRODUCTION
Epidural analgesia in labor has become a common intervention in most perinatal services. Approximately 50 to 75% of women admitted to a birthing center have epidural analgesia as a primary mode of pain relief. Although the practice started with the use of a local anesthetic agent alone, the addition of an opioid in the parturient was later recognized to enhance the onset of analgesia and provide better pain relief with decreased motor blockade. Most commonly a combination of bupivacaine (a local anaesthetic) and fentanyl (an opioid) is used to achieve optimum control of pain. The general perception among pediatricians and obstetricians is that epidural opioids in laboring women do not cause respiratory depression in newborns because the drug is contained at the site of administration. Over the last few months, we have identified several cases of respiratory depression in babies following maternal epidural analgesia with fentanyl, who responded promptly to naloxone.
CASE REPORT #1
The patient was a 3235 g male infant, born to a 27-year-old primigravida mother at 39 weeks gestation after an unremarkable antenatal course. Membranes were ruptured for 14 hours prior to admission. The mother was commenced on antibiotics and induced with oxytocin. Following onset of regular uterine contractions, she was started on patient controlled, continuous epidural analgesia with a mixture of marcaine and fentanyl. The intrapartum period was uneventful. The baby was delivered 12 hours after the onset of epidural analgesia. The mother received over 400 mg of epidural fentanyl and no parenteral opioids were administered during her entire labor.
The baby had no respiratory effort at birth. He responded to bag and mask ventilation, but remained apneic for the next few minutes with a normal heart rate and color. A decision was made to give 0.4 mg of naloxone, intramuscularly and the baby gradually improved in muscle tone and developed sustained respiratory effort. Apgar scores were 3 and 8 at 1 and 5 minutes, respectively. Cord gases were normal. The baby was observed in the special care nursery where no further problems occurred. Cord blood fentanyl levels were not performed because the assay is unavailable in our center.
CASE REPORT #2
The patient was a 3550 g male infant at 40 weeks gestation, born to a 27-year-old gravida 3, para 2 mother with a normal antenatal course. The mother was admitted for induction of labor at term in view of a history of one previous stillbirth at a similar gestational age. Oxytocin was commenced and following onset of regular uterine contractions she was started on patient regulated, continuous epidural fentanyl analgesia. The baby delivered 5 hours later. The mother received over 260 mg of fentanyl and no parenteral opioids.
There was mild meconium staining of the amniotic fluid at delivery and the infant had Apgar scores of 6 at 1 minute and 9 at 5 minutes. Cord blood gases were normal. The baby was initially slow to breathe and then sustained normal respiratory effort. However, on transfer to the special care nursery for observation, he subsequently became hypotonic with onset of irregular shallow breathing. At 15 minutes following birth, 0.4 mg naloxone was administered intramuscularly. Within minutes, the baby became more responsive and established a regular breathing pattern and then remained asymptomatic.
DISCUSSION
A review of the literature revealed similar sporadic cases of neonatal respiratory depression following epidural fentanyl analgesia. 1, 2 More recently, a randomized controlled trial (RCT) with 54 cases allocated to epidural fentanyl, did not show significant differences in any short-term neonatal outcomes. Umbilical cord arterial and venous gas measurements, Apgar scores at 1 and 5 minutes, transcutaneous O 2 and CO 2 measurements and stages of alertness were similar in infants in both arms of the study. 3 However, the study was not adequately powered to detect a statistically significant difference in the outcome of respiratory depression.
After a careful evaluation of the intrapartum progress of our cases, we recognized that a higher dose of fentanyl was being administered to women in labor as part of our management protocol. We currently use a bolus dose of 100 mg fentanyl at the onset, followed by a continuous drip delivering 20 to 32 mg/hour. Patients are then allowed to self-trigger a dose of 10 mg fentanyl to further alleviate pain as required, with an intervening lockout period of 10 minutes providing an additional dose of up to 60 mg/ hour. Based on this policy, an individual patient could receive a total dose of 180 to 192 mg of fentanyl in the first hour, followed by 80 to 92 mg/hour thereafter. In the trial by Porter et al., a continuous infusion of opioid was used without a bolus or additional patient-triggered doses. The women received a mean dose of 183 mg (standard deviation±75 mg) of fentanyl during the entire course of labor (mean duration 12 hours). Many centres may be using dosage protocols similar to ours rather than that reported in the trial by Porter et al. 3 At least three questions need to be addressed to establish a link between neonatal respiratory depression and epidural fentanyl analgesia. Firstly, how well does the drug diffuse from the epidural space into the maternal circulation. Secondly, how much of the drug in the maternal circulation gets transferred across the placenta. Thirdly, what maternal and neonatal drug levels are specifically associated with neonatal respiratory depression.
Contrary to the widely held belief, fentanyl diffuses freely from the epidural space into the maternal blood because of its high lipid solubility. Equilibrium is reached within 10 to 30 minutes. 4 The drug is also freely transported across the placenta with a slightly higher concentration in the fetal compartment, because of a comparatively acidic pH. 5 Moreover, because of the higher volume of distribution in a steady state, a larger amount of fentanyl is deposited in the fetal peripheral tissues.
Healthy adults and children tend to present with frequent apnea when plasma fentanyl levels exceed 2 ng/ml. 6, 7 There is no consensus on the dose of fentanyl causing respiratory depression in the newborn period. However, it appears that neonates are prone to respiratory depression at a lower concentration because of the immaturity of their respiratory center. 8 They are also more susceptible to respiratory depression because of an interesting phenomenon described in several reports, of a delayed rise of plasma fentanyl levels up to several hours following discontinuation of the infusion. [8] [9] [10] [11] [12] Neonatal respiratory depression related to fentanyl is more related to the amount of drug received within 2 to 4 hours preceding delivery than that used during the entire course of labor. It is not easy to pinpoint with complete certainty, which baby will have respiratory depression following birth because of wide variations in fentanyl maternal-placental-fetal kinetics. However, it can be extrapolated from the current evidence that babies delivered after mothers have received >300 mg fentanyl (approx. 5 mg/kg) during the last 4 hours of labor, may be at greater risk. 4, 5, 8 None of the trials published to date have an adequate sample size to detect a statistically significant difference for the outcome of respiratory depression in the newborn. 2, 3, 13 A prospective cohort study with an a error of 0.05 and power of 80% would require approximately 500 subjects in each arm to detect a clinically sizable difference between the groups (calculations done for a desired relative risk of Z2 and for a baseline risk of approximately 3% for respiratory depression at birth in term babies).
14 Such a study should also assess other relevant secondary outcomes related to opioids, for example, the incidence of transient tachypnea of the newborn and the need for oxygen or positive pressure ventilation in the first few hours of life.
The purpose of this report is to raise awareness of a theoretical rationale that helps to better delineate the association of neonatal respiratory depression with the use of epidural opioid analgesia. In general, this problem is more likely to manifest in neonates when mothers receive relatively large amounts of fentanyl during labor. Until proper scientific evidence is available from a rigorously designed clinical trial, the use of naloxone should be considered in the management of neonatal respiratory depression of undermined etiology following maternal intrapartum therapy with epidural opioids.
